<DOC>
	<DOCNO>NCT01737359</DOCNO>
	<brief_summary>This double-blind Phase 2a study test safety efficacy investigational HIV drug , amdoxovir ( 300 mg 500 mg twice daily ) compare tenofovir DF 300 mg daily HIV-1 infected antiretroviral therapy-experienced subject currently fail antiretroviral therapy . There three treatment group ( N=45 ) . Subjects randomize receive either amdoxovir 300 mg twice daily ( n=15 ) amdoxovir 500 mg twice daily ( n=15 ) tenofovir DF 300 mg daily ( n=15 ) ; combination zidovudine 300 mg twice daily . The study ass initially amdoxovir ( 300 mg 500 mg twice daily ) tenofovir DF 300 mg daily , combination zidovudine 300 mg twice daily plus failing third drug , lopinavir/ritonavir ( 400 mg/100 mg twice daily ) Week 2 . Subjects receive amdoxovir ( 300 mg 500 mg twice daily ) benefit drug may choose enroll 36-week open-label study .</brief_summary>
	<brief_title>A Safety Efficacy Study Amdoxovir HIV-1 Treatment-experienced Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Male female ≥ 18 year old HIV1 RNA ≥ 2,000 copies/mL currently fail therapy . Has M184I/V mutation addition 02 thymidine analog mutation ( TAMs ) screening . Agree abstinent use two reliable form contraception ( female ) one form men participate sexual activity could result pregnancy . Current recent ( last 30 day study entry ) AIDS defining disease . Genotypic resistance test screen indicate K65R , L74V , Q151M mutation . Prior exposure lopinavir/ritonavir amdoxovir . Impaired hepatic function ( ALT &gt; 5 x ULN ) . Women pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>amdoxovir</keyword>
	<keyword>zidovudine</keyword>
	<keyword>tenofovir DF</keyword>
	<keyword>HIV</keyword>
	<keyword>HAART</keyword>
	<keyword>antiretroviral</keyword>
</DOC>